Technologies for the development of West Nile virus vaccines

Future Microbiology

Volumn 9, Issue 10, 2014, Pages 1221-1232

  Ulbert, Sebastian ^a   Magnusson, Sofia E ^b  

^a FRAUNHOFER INSTITUTE FOR CELL THERAPY AND IMMUNOLOGY   (Germany)

^b NOVAVAX INC   (United States)

Author keywords

Animal models; Emerging virus; Protective immune responses; Vaccine development; West Nile Virus

Indexed keywords

DNA VACCINE; INACTIVATED VIRUS VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; VIRUS VECTOR; WEST NILE VACCINE;

DRUG EFFICACY; DRUG SAFETY; EUROPE; FLAVIVIRUS INFECTION; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; LICENSING; NEUROLOGIC DISEASE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; UNITED STATES; VACCINATION; VACCINE PRODUCTION; VETERINARY MEDICINE; VIRUS IMMUNITY; WEST NILE FLAVIVIRUS; ANIMAL; EPIDEMIOLOGY; IMMUNOLOGY; ISOLATION AND PURIFICATION; VETERINARY; WEST NILE FEVER; WEST NILE VIRUS;

ANIMALIA; WEST NILE VIRUS;

ANIMALS; EUROPE; HUMANS; UNITED STATES; WEST NILE FEVER; WEST NILE VIRUS; WEST NILE VIRUS VACCINES;

EID: 84911484406     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.14.67     Document Type: Review

References (100)

1. Gubler DJ, Kuno G, Markoff L. Flaviviruses. In: Fields Virology (5th Edition). Knipe DM, Howley PM (Eds). Lippincott Williams and Wilkins, Philadelphia, PA, USA, 1155-1252 (2007).
2. Hayes EB, Sejvar JJ, Zaki SR, Lanciotti RS, Bode AV, Campbell GL. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg. Infect. Dis. 11, 1174-1179 (2005).
3. Papa A. West Nile virus infections in humans - focus on Greece. J Clin. Virol. 58, 351-353 (2013).
4. Murray KO, Mertens E, Desprès P. West Nile virus and its emergence in the United States of America. Vet. Res. 41, 67 (2010).
5. LaDeau SL, Kilpatrick AM, Marra PP. West Nile virus emergence and large-scale declines of North American bird populations. Nature 447, 710-713 (2007).
6. Lanciotti RS, Ebel GD, Deubel V et al. Complete genome sequences and phylogenetic analysis of West Nile virus strains isolated from the United States, Europe, and the Middle East. Virology 298, 96-105 (2002).
7. Botha EM, Markotter W, Wolfaardt M et al. Genetic determinants of virulence in pathogenic lineage 2 West Nile virus strains. Emerg. Infect. Dis. 14, 222-230 (2008).
8. Papa A, Xanthopoulou K, Gewehr S, Mourelatos S. Detection of West Nile virus lineage 2 in mosquitoes during a human outbreak in Greece. Clin. Microbiol. Infect. 17(8), 1176-1180 (2011).
9. Bakonyi T, Ferenczi E, Erdélyi K et al. Explosive spread of a neuroinvasive lineage 2 West Nile virus in Central Europe, 2008/2009. Vet. Microbiol. 165(1-2), 61-70 (2013).
10. Magurano F, Remoli ME, Baggieri M et al. Circulation of West Nile virus lineage 1 and 2 during an outbreak in Italy. Clin. Microbiol. Infect. 18, 545-547 (2012).
11. Barzon L, Pacenti M, Franchin E et al. The complex epidemiological scenario of West Nile virus in Italy. Int. J. Environ. Res. Public Health. 10, 4669-4689 (2013).
12. Mukhopadhyay S, Kuhn RJ, Rossmann MG. A structural perspective of the flavivirus life cycle. Nat. Rev. Microbiol. 3(1), 13-22 (2005).
13. Chung KM, Thompson BS, Fremont DH, Diamond MS. Antibody recognition of cell surface-associated NS1 triggers Fc-gamma receptor-mediated phagocytosis and clearance of West Nile Virus-infected cells. J. Virol. 81, 9551-9555 (2007).
14. Chung KM, Diamond MS. Defining the levels of secreted non-structural protein NS1 after West Nile virus infection in cell culture and mice. J. Med. Virol. 80(3), 547-556 (2008).
15. Chung KM, Nybakken GE, Thompson BS et al. Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptordependent and -independent mechanisms. J. Virol. 80, 1340-1351 (2006).
16. Chung KM, Liszewski MK, Nybakken G et al. West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H. Proc. Natl Acad. Sci. USA 103, 19111-19116 (2006).
17. Arjona A, Ledizet M, Anthony K et al. West Nile virus envelope protein inhibits dsRNA-induced innate immune responses. J. Immunol. 179, 8403-8409 (2007).
18. Laurent-Rolle M, Boer EF, Lubick KJ et al. The NS5 protein of the virulent West Nile virus NY99 strain is a potent antagonist of type I interferon-mediated JAK-STAT signaling. J. Virol. 84, 3503-3515 (2010).
19. Halstead SB, Thomas SJ. Japanese Encephalitis: New Options for Active Immunization. Clin. Infect. Dis. 50, 1155-1164 (2010).
20. Ishikawa T, Yamanaka A, Konishi E. A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available. Vaccine 32, 1326-1337 (2014).
21. Ng T, Hathaway D, Jennings N, Champ D, Chiang YW, Chu HJ. Equine vaccine for West Nile virus. Dev. Biol. (Basel) 114, 221-227 (2003).
22. El Garch H, Minke JM, Rehder J et al. A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse. Vet. Immunol. Immunopathol. 123, 230-239 (2008).
23. Gardner IA, Wong SJ, Ferraro GL et al. Incidence and effects of West Nile virus infection in vaccinated and unvaccinated horses in California. Vet. Res. 38(1), 109-116 (2007).
24. Iyer AV, Kousoulas KG. A review of vaccine approaches for West Nile virus. Int. J. Environ. Res. Public Health. 10(9), 4200-4223 (2013).
25. Diamond MS, Mehlhop E, Oliphant T, Samuel MA. The host immunologic response to West Nile encephalitis virus. Front. Biosci. 14, 3024-3034 (2009).
26. Lim SM, Koraka P, Osterhaus AD, Martina BE. West Nile virus: immunity and pathogenesis. Viruses 3(6), 811-828 (2011).
27. Netland J, Bevan MJ. CD8 and CD4 T cells in west nile virus immunity and pathogenesis. Viruses 5(10), 2573-2584 (2013).
28. Suthar MS, Diamond MS, Gale M Jr. West Nile virus infection and immunity. Nat. Rev. Microbiol. 11(2), 115-128 (2013).
29. Diamond MS, Shrestha B, Marri A, Mahan D, Engle M. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J. Virol. 77, 2578-2586 (2003).
30. Diamond MS, Sitati EM, Friend LD, Higgs S, Shrestha B, Engle M. A critical role for induced IgM in the protection against West Nile virus infection. J. Exp. Med. 198, 1853-1862 (2003).
31. Oliphant T, Engle M, Nybakken GE et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 11(5), 522-530 (2005).
32. Beigel JH, Nordstrom JL, Pillemer SR et al. Safety and pharmacokinetics of single intravenous dose of MGAWN1, a novel monoclonal antibody to West Nile virus. Antimicrob. Agents Chemother. 54(6), 2431-2436 (2010).
33. Purtha WE, Tedder TF, Johnson S, Bhattacharya D, Diamond MS. Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants. J. Exp. Med. 208(13), 2599-2606 (2011).
34. Mehlhop E, Nelson S, Jost CA et al. Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus. Cell Host Microbe 6(4), 381-391 (2009).
35. Shrestha B, Ng T, Chu HJ, Noll M, Diamond MS. The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus. Vaccine 26, 2020-2033 (2008).
36. Wang T, Anderson JF, Magnarelli LA, Wong SJ, Koski RA, Fikrig E. Immunization of mice against West Nile virus with recombinant envelope protein. J. Immunol. 167(9), 5273-5277 (2001).
37. Chabierski S, Makert GR, Kerzhner A et al. Antibody responses in humans infected with newly emerging strains of West Nile Virus in Europe. PLoS ONE 8(6), e66507 (2013).
38. Vázquez S, Guzmán MG, Guillen G et al. Immune response to synthetic peptides of dengue prM protein. Vaccine 20(13-14), 1823-1830 (2002).
39. Beasley DW, Barrett AD. Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J. Virol. 76, 13097-13100 (2002).
40. Diamond MS, Pierson TC, Fremont DH. The structural immunology of antibody protection against West Nile virus. Immunol. Rev. 225, 212-225 (2008).
41. Oliphant T, Nybakken GE, Austin SK et al. Induction of epitope-specific neutralizing antibodies against West Nile virus. J. Virol. 81, 11828-11839 (2007).
42. Chu JH, Chiang CC, Ng ML. Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection. J. Immunol. 178(5), 2699-2705 (2007).
43. Martina BE, Koraka P, van den Doel P, van Amerongen G, Rimmelzwaan GF, Osterhaus AD. Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus. Vaccine 26, 153-157 (2008).
44. Throsby M, Geuijen C, Goudsmit J et al. Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus. J. Virol. 80, 6982-6992 (2006).
45. Vogt MR, Dowd KA, Engle M et al. Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complementdependent effector mechanisms. J. Virol 85, 11567-11580 (2011).
46. Ferguson M, Wood DJ, Minor PD. Antigenic structure of poliovirus in inactivated vaccines. J. Gen. Virol . 74(4), 685-690 (1993).
47. Brown F. Review of accidents caused by incomplete inactivation of viruses. Dev. Biol. Stand. 81, 103-107 (1993).
48. Amanna IJ, Raué HP, Slifka MK. Development of a new hydrogen peroxide-based vaccine platform. Nat. Med. 18(6), 974-979 (2012).
49. Yamshchikov G, Borisevich V, Seregin A. An attenuated West Nile prototype virus is highly immunogenic and protects against the deadly NY99 strain: a candidate for live WN vaccine development. Virology 330(1), 304-312 (2004).
50. Schlick P, Kofler RM, Schittl B et al. Characterization of West Nile virus live vaccine candidates attenuated by capsid deletion mutations. Vaccine 28, 5903-5909 (2010).
51. Widman DG, Ishikawa T, Giavedoni LD et al. Evaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a nonhuman primate model of West Nile virus infection. Am. J. Trop. Med. Hyg. 82, 1160-1167 (2010).
52. Whiteman MC, Li L, Wicker JA. Development and characterization of non-glycosylated E and NS1 mutant viruses as a potential candidate vaccine for West Nile virus. Vaccine 28(4), 1075-1083 (2010).
53. Wang T, Anderson JF, Magnarelli LA, Wong SJ, Koski RA, Fikrig E. Immunization of Mice Against West Nile Virus with Recombinant Envelope Protein. J. Immunology 167, 5273-5277 (2001).
54. Ledizet M, Kar K, Foellmer HG et al. A recombinant envelope protein vaccine against West Nile virus. Vaccine 23, 3915-3924 (2005).
55. Lieberman MM, Clements DE, Ogata S et al. Preparation and immunogenic properties of a recombinant West Nile subunit vaccine. Vaccine 25(3), 414-423 (2007).
56. Bonafé N, Rininger JA, Chubet RG et al. A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells. Vaccine 27(2), 213-222 (2009).
57. Watts DM, Tesh RB, Siirin M et al. Efficacy and durability of a recombinant subunit West Nile vaccine candidate in protecting hamsters from West Nile encephalitis. Vaccine 25( 15), 2913-2918 (2007).
58. Lieberman MM, Nerurkar VR, Luo H et al. Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys. Clin. Vaccine Immunol. 16(9), 1332-1337 (2009).
59. ClinicalTrials.gov. NCT00707642. http://clinicaltrials.gov/show/NCT00707642
60. Magnusson SE, Karlsson KH, Reimer JM et al. Matrix-M™ adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice. Vaccine 32(7), 800-808 (2014).
61. Reimer JM, Karlsson KH, Lövgren-Bengtsson K, Magnusson SE, Fuentes A, Stertman L. Matrix-M™ adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen. PLoS ONE 7(7), e41451 (2012).
62. Magnusson SE, Reimer JM, Karlsson KH, Lilja L, Bengtsson KL, Stertman L. Immune enhancing properties of the novel Matrix-M™ adjuvant leads to potentiated immune responses to an influenza vaccine in mice. Vaccine 31(13), 1725-1733 (2013).
63. Cox RJ, Pedersen G, Madhun AS et al. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial. Vaccine 29(45), 8049-8059 (2011).
64. Chu JH, Chiang CC, Ng ML. Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection. J. Immunol. 178(5), 2699-2705 (2007).
65. Zlatkovic J, Stiasny K, Heinz FX. Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice. J. Virol. 85(5), 1994-2003 (2011).
66. McDonald WF, Huleatt JW, Foellmer HG et al. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. J. Infect. Dis. 195(11), 1607-1617 (2007).
67. Davis BS, Chang GJ, Cropp B et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J. Virol. 75, 4040-4047 (2001).
68. De Filette M, Ulbert S, Diamond M, Sanders NN. Recent progress in West Nile virus diagnosis and vaccination. Vet. Res. 43, 16 (2012).
69. Martin JE, Pierson TC, Hubka S et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J. Infect. Dis. 196, 1732-1740 (2007).
70. Ledgerwood JE, Pierson TC, Hubka SA et al. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J. Infect. Dis. 203(10), 1396-1404 (2011).
71. Schneeweiss A, Chabierski S, Salomo M et al. A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII. Vaccine 29(37), 6352-6357 (2011).
72. Dunn MD, Rossi SL, Carter DM et al. Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice. Virol. J. 7, 95 (2010).
73. Chang DC, Liu WJ, Anraku I et al. Single-round infectious particles enhance immunogenicity of a DNA vaccine against West Nile virus. Nat. Biotechnol. 26(5), 571-577 (2008).
74. Lechardeur D, Lukacs GL. Intracellular barriers to non-viral gene transfer. Curr. Gene Ther. 2(2), 183-194 (2002).
75. Li L, Saade F, Petrovsky N. The future of human DNA vaccines. J. Biotechnol. 162(2-3), 171-182 (2012).
76. Suh H, Shin J, Kim YC. Microneedle patches for vaccine delivery. Clin. Exp. Vaccine Res. 3(1), 42-49 (2014).
77. De Filette M, Soehle S, Ulbert S et al. Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge. PLoS ONE 9(2), e87837 (2014).
78. Calarota SA, Weiner DB, Lori F, Lisziewicz J. Induction of HIV-specific memory T-cell responses by topical DermaVir vaccine. Vaccine 25(16), 3070-3074 (2007).
79. Lu S. Heterologous prime-boost vaccination. Curr. Opin. Immunol. 21, 346-351 (2009).
80. Ishikawa T, Takasaki T, Kurane I, Nukuzuma S, Kondo T, Konishi E. Co-immunization with West Nile DNA and inactivated vaccines provides synergistic increases in their immunogenicities in mice. Microbes Infect. 9, 1089-1095 (2007).
81. Prow TW, Chen X, Prow NA et al. Nanopatch-targeted skin vaccination against West Nile Virus and Chikungunya virus in mice. Small 6(16), 1776-1784 (2010).
82. Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 28, 632-649 (2010).
83. Biedenbender R, Bevilacqua J, Gregg AM et al. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults. J. Infect. Dis. 203, 75-84 (2011).
84. Brandler S, Tangy F. Vaccines in development against West Nile virus. Viruses 5(10), 2384-2409 (2013).
85. Durbin AP, Wright PF, Cox A et al. The live attenuated chimeric vaccine rWN/DEN4d30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers. Vaccine 31(48), 5772-5777 (2013).
86. Brandler S, Marianneau P, Loth P et al. Measles vaccine expressing the secreted form of West Nile virus envelope glycoprotein induces protective immunity in squirrel monkeys, a new model of West Nile virus infection. J. Infect. Dis. 206(2), 212-219 (2012).
87. Iyer AV, Pahar B, Boudreaux MJ et al. Recombinant vesicular stomatitis virus-based west Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent west Nile virus strain LSU-AR01. Vaccine 27(6), 893-903 (2009).
88. Martina BE, van den Doel P, Koraka P et al. A recombinant influenza A virus expressing domain III of West Nile virus induces protective immune responses against influenza and West Nile virus. PLoS ONE 6(4), e18995 (2011).
89. Iglesias MC, Frenkiel MP, Mollier K, Souque P, Despres P, Charneau P. A single immunization with a minute dose of a lentiviral vector-based vaccine is highly effective at eliciting protective humoral immunity against West Nile virus. J. Gene. Med. 8(3), 265-274 (2006).
90. Schepp-Berglind J, Luo M, Wand D et al. Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses. Clin. Vaccine Immunol. 14(9), 1117-1126 (2007).
91. Lindsey NP, Staples JE, Lehman JA, Fischer M. Centers for Disease Control and Prevention (CDC). Surveillance for human West Nile virus disease - United States, 1999-2008. MMWR Surveill. Summ. 59(2), 1-17 (2010).
92. Boraschi D, Del Giudice G, Dutel C, Ivanoff B, Rappuoli R, Grubeck-Loebenstein B. Ageing and immunity: addressing immune senescence to ensure healthy ageing. Vaccine 28(21), 3627-3631 (2010).
93. Pinto AK, Richner JM, Poore EA et al. A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice. J. Virol. 87(4), 1926-1936 (2013).
94. Magurano F, Remoli ME, Baggieri M et al. Circulation of West Nile virus lineage 1 and 2 during an outbreak in Italy. Clin. Microbiol. Infect. 18, E545-547 (2012).
95. Venter M, van Vuren PJ, Mentoor J, Paweska J, Williams J. Inactivated West Nile Virus (WNV) vaccine, Duvaxyn WNV, protects against a highly neuroinvasive lineage 2 WNV strain in mice. Vaccine 31(37), 3856-3862 (2013).
96. Minke JM, Siger L, Cupillard L et al. Protection provided by a recombinant ALVAC®-WNV vaccine expressing the prM/E genes of a lineage 1 strain of WNV against a virulent challenge with a lineage 2 strain. Vaccine 29(28), 4608-4612 (2011).
97. Erra EO, Askling HH, Yoksan S et al. Cross-protective capacity of Japanese encephalitis (JE) vaccines against circulating heterologous JE virus genotypes. Clin. Infect. Dis. 56, 267-270 (2013).
98. Centers for Disease Control and Prevention. West Nile virus. www.cdc.gov
99. Dayan GH, Pugachev K, Bevilacqua J, Lang J, Monath TP., Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus. Viruses 5(12), 3048-3070 (2013).
100. Vazquez A, Sanchez-Seco MP, Ruiz S et al. Putative new lineage of west nile virus, Spain. Emerg. Infect. Dis.. 16, 549-552 (2010).